Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. Full Text available with Trip Pro

Prostate Cancer Care and Outcomes Study (PCOS).General health and disease specific quality of life were self-reported at seven time points over a 15 year period, using the 12-item Short Form Health Survey scale, University of California, Los Angeles prostate cancer index, and expanded prostate cancer index composite short form (EPIC-26). Adjusted mean differences were calculated with controls as the comparison group. Clinical significance of adjusted mean differences was assessed by the minimally (...) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. To assess treatment related changes in quality of life up to 15 years after diagnosis of localised prostate cancer.Population based, prospective cohort study with follow-up over 15 years.New South Wales, Australia.1642 men with localised prostate cancer, aged less than 70, and 786 controls randomly recruited from the New South Wales electoral roll into the New South Wales

2020 BMJ

2. Cancer control plans

Cancer control plans Cancer control plans - Sax Institute - Sax Institute × Close Sign up for our newsletter Name Email * Position Centre Subscribe Cancer control plans The 45 and Up Study Learn more about our research into healthy ageing × The 45 and Up Study Cancer control plans ) for the Cancer Institute NSW 2020. Date of publication: June 2020 Download (PDF 792 KB)

2020 Sax Institute Evidence Check

3. Avelumab (Bavencio) - advanced renal cell carcinoma (RCC).

= stable disease. Objective response rate was defined as complete or partial response on response evaluation criteria in solid tumours (RECIST) version 1.1 by blinded independent committee review (BICR). At interim analysis-2 quality of life was similar in the avelumab plus axitinib group and sunitinib group as measured on the EuroQol five dimension five level (EQ-5D-5L), functional assessment of 4 cancer therapy – kidney symptom index 19 (FKSI-19) and functional assessment of cancer therapy – disease (...) renal cell carcinoma is an incurable, heterogeneous cancer and not all patients respond to treatment. The disease symptoms have a negative impact on the quality of life of patients and make daily living difficult. Anecdotal evidence suggests an increasing number of younger patients have been diagnosed in recent years and symptoms may also affect their ability to look after family and/or work. ? There is an unmet need for a greater choice of treatment options and since approximately 50% of patients

2020 Scottish Medicines Consortium

4. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment Full Text available with Trip Pro

excision, especially those with high-risk pT1 and pT2 rectal cancer. The lowest recurrence risk is provided by cTME; aCRT has outcomes comparable to those of cTME for high-risk pT1 tumours, but shows a higher risk for pT2 tumours. Antecedentes: Tras una resección temprana de un cáncer de recto localizado, hay que considerar el equilibrio entre el riesgo de recidiva local y la morbilidad relacionada con el tratamiento. El objetivo de este metaanálisis era determinar los resultados oncológicos tras la (...) Review. Show more similar articles References Steele RJC, McClements P, Watling C, Libby G, Weller D, Brewster DH et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61: 576-581. Morris EJA, Whitehouse LE, Farrell T, Nickerson C, Thomas JD, Quirke P et al. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer

2020 EvidenceUpdates

5. Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer

Permalink Copy Page navigation Ann Surg Actions . 2020 Nov;272(5):684-689. doi: 10.1097/SLA.0000000000004340. Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. 2 Department of Clinical Science, Intervention (...) and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Klara Nilsson et al. Ann Surg . 2020 Nov . Show details Display options Display options Format Ann Surg Actions . 2020 Nov;272(5):684-689. doi: 10.1097/SLA.0000000000004340. Authors , , , , , , , , , , , , , , , , Affiliations 1 Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. 2 Department

2020 EvidenceUpdates

6. Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis Full Text available with Trip Pro

a shorter duration with 1 year of trastuzumab as adjuvant treatment, and include patients with early breast cancer. Data extraction and synthesis: Individual patient data for disease-free survival (DFS) and overall survival (OS) were extracted from published survival curves of included RCTs; DFS and OS curves for each trial and the combined population were reconstructed. The DFS and OS hazard ratios (HRs) were estimated from the reconstructed survival curves as well as published estimates. The HR (...) Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2020 EvidenceUpdates

7. Performance of (18)F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis

to 85.6), 98.9% (95% CI, 94.3 to 99.7), and 17.9% (95% CI, 8.5 to 33.6), respectively. Conclusion: FDG PET/CT appears to have satisfactory accuracy indices for cancer diagnosis in patients with unprovoked VTE. In particular, it exhibits a very high negative predictive value and could be used to rule out the presence of an underlying occult malignancy in this setting. Keywords: Fluorodeoxyglucose F18; Neoplasms; Positron-emission tomography; Screening; Venous thromboembolism. Copyright © 2020 Elsevier (...) Performance of (18)F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis Performance of 18 F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis - PubMed This site needs JavaScript to work properly. Please

2020 EvidenceUpdates

8. Metastatic Carcinoma and Myeloma of the Femur

Quality and Value Department 4. Tyler Verity, BA Medical Librarian, AAOS Clinical Quality and Value Department11 INTRODUCTION Overview The skeleton is a frequent site of metastasis in patients with cancer. Multiple myeloma is a plasma cell malignancy in which 70-80% of patients present with lytic lesions in the skeleton (Terpos, 2013). Bone lesions, whether from metastatic carcinoma or multiple myeloma, can be painful and limit physical activity. They may require radiation therapy, surgery or both (...) of age, sex, race, ethnicity, education, or socioeconomic status. Burden of Disease The skeleton is a frequent site of metastatic carcinoma and myeloma. Primary sites of disease that commonly metastasize to bone include breast, lung, prostate, kidney, and thyroid. The National Cancer Institute (NCI) estimates new cases in 2017 at 252,710 for breast, 222,500 for lung, 161,360 for prostate, and 63,990 for kidney (2019). Autopsy studies have shown an incidence of bone metastases of approximately 70

2020 American Society of Clinical Oncology Guidelines

9. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation Full Text available with Trip Pro

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (...) (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study concluded that the existing evidence cannot provide decision-makers with clear guidance on the comparative effectiveness or cost-effectiveness of selective internal radiation therapies for unresectable hepatocellular carcinoma

2020 NIHR HTA programme

10. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) T echnology appraisal guidance Published: 7 October 2020 www.nice.org.uk/guidance/ta652 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) -of- rights).Contents Contents Advice 3 Information 3 Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

mutation-positive advanced non-small-cell lung cancer (TA653) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 17This guidance replaces TA416. 1 1 Recommendations Recommendations 1.1 Osimertinib is recommended as an option for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non- small-cell lung cancer (NSCLC) in adults, only if: • their disease has progressed (...) it appropriate to stop. Why the committee made these recommendations Why the committee made these recommendations This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for osimertinib for treating EGFR T790M mutation-positive locally advanced or metastatic NSCLC for adults whose disease has progressed after treatment with an EGFR tyrosine kinase inhibitor (NICE technology appraisal guidance 416). EGFR T790M mutation-positive locally advanced

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Osimertinib for untreated EGFR mutation-positive non- small-cell lung cancer T echnology appraisal guidance Published: 14 October 2020 www.nice.org.uk/guidance/ta654 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20Contents Contents 1 Recommendation 4 2 Information about osimertinib 5 Marketing authorisation

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

13. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

with intermediate or poor-risk cancer as defined by the International Metastatic Renal Cell Carcinoma Database Consortium. Nivolumab with ipilimumab and avelumab with axitinib are available through the Cancer Drugs Fund. Because they are not established practice, they cannot be comparators in this appraisal. Short-term clinical trial evidence shows that pembrolizumab with axitinib is more effective than sunitinib for people with untreated renal cell carcinoma, but it is uncertain if there is a long-term benefit (...) issues (issues 1, 2, 5, 7, 8, and 9), which were outstanding after the technical engagement stage. New treatment option New treatment option People with untreated renal cell carcinoma would welcome a new People with untreated renal cell carcinoma would welcome a new treatment option treatment option 3.1 In England, kidney cancer is expected to cause about 3,783 deaths every year, with 10,759 new cases per year. Of people with kidney cancer, 80% have renal cell carcinoma. A patient expert explained

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

14. Identifying Features of Screening Approaches for People at Increased Risk of Colorectal Cancer

quality and three of medium quality. • When defining individuals at average CRC risk, most guidelines included those who are above the age of 50 years with no personal or family history of CRC, with no hereditary syndromes (such as familial adenomatous polyposis or Lynch syndrome), and without a history of abdominal or pelvic radiation, previous cancer or history of inflammatory bowel disease. Additionally, we found similarities among the guidelines when describing different screening approaches (...) screening programs across Canada.(3) To ensure appropriate triage and management for CRC, there is a need to ensure screening programs are identifying individuals deemed to be at ‘increased risk’ of developing colorectal cancer due to familial or personal-health histories. Though definitions vary, individuals at ‘average risk’ for CRC generally refers to people between the ages of 50-74 years of age, with no personal history of CRC, polyps, inflammatory bowel disease or symptoms of CRC, and no family

2020 McMaster Health Forum

15. Post-Treatment Surveillance of Bladder Cancer

with bladder carcinoma, DWI was found to have a sensitivity of 90%, a specificity of 93%, and an accuracy of 91% compared with cystoscopy [70]. El-Assmy et al [71] recently compared staging accuracy of DWI to T2-weighted sequences, finding superior performance of DWI in staging organ-confined tumors less than or equal to T2 disease. Likewise, Takeuchi et al [72] found that DWI added information when evaluating the T stage of bladder cancer, significantly improving accuracy, specificity, and area under (...) , Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999;162(3 Pt 1):710-714. 85. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002;9(4):335-342. 86. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol

2020 American College of Radiology

16. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines Full Text available with Trip Pro

controls and patients with other malignancies. J Assist Reprod Genet. 2016; 33 : 657-662 Recommendations • All cancer patients of reproductive age should receive complete oncofertility counselling as early as possible in the treatment planning process, irrespective of the type and stage of disease [III, A]. • Oncofertility counselling should be individualised based on patient/couple- and disease/treatment-related factors, with patient interest and age as well as type of treatment being the most (...) related to IVF outcomes. Hum Reprod. 2018; 33 : 2222-2231 While some studies have reported that the number of recovered oocytes in women with cancer is not reduced, von Wolff M. Bruckner T. Strowitzki T. Germeyer A. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stimulations. J Assist Reprod Genet. 2018; 35 : 1713-1719 others have found a reduction (particularly in lymphoma patients), with reduced fertilisation

2020 European Society for Medical Oncology

17. Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer Oregon Health Authority : Evidence-based Reports Blog : Health Evidence Review Commission : State of Oregon menu Toggle Main Menu Main Navigation close search Search search Submit You are here: Evidence-based Reports Blog menu Site Navigation Evidence-based Reports Blog Full Width Column 1 Select Ablation for Atrial Fibrillation Acellular Dermal Matrix for Post-Mastectomy Breast Reconstruction Compliance (...) ={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null); 0x0 0x1 ContentType 0x01 898 BlogTopic Multicomponent Interventions to Improve Screening for Breast, Cervical or Colorectal Cancer

2020 Oregon Health Evidence Review Commission

18. Ripretinib (Qinlock) - for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST

Ripretinib (Qinlock) - for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent

2020 Health Canada - Drug and Health Product Register

19. Copper Cu 64 dotatate injection (Detectnet) - To help detect certain types of neuroendocrine tumors

Copper Cu 64 dotatate injection (Detectnet) - To help detect certain types of neuroendocrine tumors Drug Approval Package: ENSPRYNG U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ENSPRYNG Company: RadioMedix, Inc. Application Number: 213227 Approval Date: 9/3/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

20. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5) Full Text available with Trip Pro

Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea N.U. Lin Affiliations Susan Smith Center for Women's Cancers – Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA S.A. Mertz Affiliations Metastatic Breast Cancer Network, Inverness, USA S. Neciosup Affiliations Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru B.V. Offersen Affiliations Department of Oncology, Aarhus University Hospital, Aarhus (...) general guidelines To date, the removal of the primary tumour in patients with de novo stage IV breast cancer has not been associated with prolongation of survival, with the possible exception of the subset of patients with bone-only disease. However, it can be considered in selected patients with controlled systemic disease, particularly to improve QoL, always taking into account the patient’s preferences. Of note, some studies suggest that surgery is only valuable if performed with the same

2020 European Society for Medical Oncology